Back to News
Sep 17, 2025 12:00 PM

GSK To Pour $30 Billion Into US R&D, Manufacturing Over Five Years

GSK plc (NYSE:GSK) on Wednesday announced plans to invest $30 billion across the United States in research and development and supply chain infrastructure over the next five years.

The update includes a new $1.2 billion investment that comprises:

Construction of an additional new biologics flex factory at Upper Merion, Pennsylvania, to deliver new medicines for respiratory disease (COPD, asthma) and cancer (haematological, gynaecological, lung and other solid tumours). Construction is planned to commence in 2026.

GSK is introducing new AI and advanced digital technology capabilities across its existing five manufacturing sites.

New drug substance manufacturing capabilities.

New and enhanced device and auto-injector capabilities and assembly.

Also Read: Robert F. Kennedy Took Fire From Both Republicans And Democrats Over Vaccine Overhauls: GOP ...